Antonio L. Dans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antonio L. Dans has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Cherian Varghese
Western Pacific Regional Office, WHO, Manila, Philippines
1 shared publication- E. Shyong Tai
Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
1 shared publication Jun Zhu
FuWai Hospital, Chinese Academy of Medical Science, Beijing, China
1 shared publicationJyh-Hong Chen
National Cheng Kung University Medical College, Tainan, Taiwan
1 shared publicationKhalid Yusoff
Universiti Teknologi MARA, Shah Alam, Malaysia
1 shared publicationKim Jae-Hyung
St. Paul's Hospital, The Catholic University of Korea, Seoul, Korea
1 shared publication
Latest Publications
- Top Cited Papers
- 1 February 2011
- Published by Elsevier in The Lancet
- Vol. 377 (9766) , 680-689
The rise of chronic non-communicable diseases in southeast Asia: time for action
- 1 February 2011
- Published by Elsevier in The Lancet
- Vol. 377 (9766) , 680-689
Top Cited PapersThe rise of chronic non-communicable diseases in southeast Asia: time for action
- Open Access
- 21 December 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (12) , e13694
In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events
Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/day) in reducing cardiovascular events. Clinicians in Asia doubt tolerability of these doses for their patients. We therefore analyzed data from this study and a parallel study TRANSCEND (Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease). Our objectives were to compare Asians and non-Asians with respect to the following: The ONTARGET study randomized 25,620 patients at risk of cardiovascular events to ramipril, telmisartan, or their combination. The primary composite endpoint was death caused by cardiovascular disease, acute MI, stroke, and hospitalization because of congestive heart failure. TRANSCEND randomized 5926 high-risk patients with a history of intolerance to ACE-inhibitors to telmisartan or placebo. The primary outcome was the same. In this substudy, we compared Asians and non-Asians as to how well they tolerated telmisartan (given in both studies) and ramipril (given in ONTARGET). 1) Telmisartan was non-inferior to ramipril in lowering the primary endpoint among Asians (RR = 0.92; 95% CI: 0.74, 1.13); 2) more Asians achieved the full dose of either drug; 3) less withdrew (overall); and 4) less withdrew for adverse effects. Furthermore, telmisartan was better tolerated than ramipril. This advantage was greater among Asians. Although Asians had lower BMI than non-Asians, Asians tolerated both drugs better. Regulatory agencies require reporting of safety and effectiveness data by ethnicity, but few comply with this requirement. This study shows that safety data in ethnic subgroups can help assess applicability of results to specific populations. ClinicalTrials.gov NCT00153101
- 21 December 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (12) , e13694
Open AccessIn a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events
Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/day) in reducing cardiovascular events. Clinicians in Asia doubt tolerability of these doses for their patients. We therefore analyzed data from this study and a parallel study TRANSCEND (Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease). Our objectives were to compare Asians and non-Asians with respect to the following: The ONTARGET study randomized 25,620 patients at risk of cardiovascular events to ramipril, telmisartan, or their combination. The primary composite endpoint was death caused by cardiovascular disease, acute MI, stroke, and hospitalization because of congestive heart failure. TRANSCEND randomized 5926 high-risk patients with a history of intolerance to ACE-inhibitors to telmisartan or placebo. The primary outcome was the same. In this substudy, we compared Asians and non-Asians as to how well they tolerated telmisartan (given in both studies) and ramipril (given in ONTARGET). 1) Telmisartan was non-inferior to ramipril in lowering the primary endpoint among Asians (RR = 0.92; 95% CI: 0.74, 1.13); 2) more Asians achieved the full dose of either drug; 3) less withdrew (overall); and 4) less withdrew for adverse effects. Furthermore, telmisartan was better tolerated than ramipril. This advantage was greater among Asians. Although Asians had lower BMI than non-Asians, Asians tolerated both drugs better. Regulatory agencies require reporting of safety and effectiveness data by ethnicity, but few comply with this requirement. This study shows that safety data in ethnic subgroups can help assess applicability of results to specific populations. ClinicalTrials.gov NCT00153101
- 1 December 2010
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 63 (12) , 1281-1282
Appraising a tool for guideline appraisal (the AGREE II instrument)
- 1 December 2010
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 63 (12) , 1281-1282
Appraising a tool for guideline appraisal (the AGREE II instrument)